Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

International Clinical Psychopharmacology

Volumn 20, Issue 4, 2005, Pages 213-221

  Lindenmayer, Jean Pierre ^a,b   Jarboe, Kathleen ^a   Bossie, Cynthia A ^a   Zhu, Young ^a   Mehnert, Angelika ^a   Lasser, Robert ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

Antipsychotic agents; Injections; Patient compliance; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MOOD STABILIZER; OLANZAPINE; PLACEBO; PROPRANOLOL; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INJECTION PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SKIN INDURATION; SKIN MANIFESTATION; VISUAL ANALOG SCALE;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PLACEBOS; RISPERIDONE; SCHIZOPHRENIA;

EID: 21244485443     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200507000-00004     Document Type: Article

References (23)

1. Adams CE, Fenton MK, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290-299.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.
3. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E (2003). Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63:493-512.
4. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233-246.
5. Awad AG, Hogan TP (1994). Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 380:27-32.
6. Babiker IE (1987). Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 43: 94-97.
7. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
8. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G (2001). Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 62:855-859.
9. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
10. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L (1994). Depot antipsychotic drugs: place in therapy. Drugs 47:741-773.
11. Docherty JP, Grogg AL, Kozma C, Lasser R (2002). Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Presented at The American College of Neuropsychopharmacology 41st Annual Meeting, 8-12 December, San Juan, Puerto Rico.
12. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108.
13. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
14. Hamann GL, Egan TM, Wells BG, Grimmig JE (1990). Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 51:502-504.
15. Kane J, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
16. Kane JM (2001). Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 11:S397-S403.
17. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8:55-66.
18. Kozma C, Grogg AL (2003). Medication compliance and hospitalization in schizophrenia. Presented at the College of Psychiatric and Neurologic Pharmacists Sixth Annual Meeting, 1-4 May, Charleston, SC.
19. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA (2004). Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Dis 83:263-275.
20. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136.
21. Quartermaine S, Taylor R (1995). A comparative study of depot injection techniques. Nursing Times 91:36-39.
22. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG (1997). Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54:549-557.
23. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40:630-639.